Effects of polymorphisms in gonadotropin and gonadotropin receptor genes on reproductive function

Reviews in Endocrine and Metabolic Disorders

Volumn 12, Issue 4, 2011, Pages 303-321

  Casarini, Livio ^a   Pignatti, Elisa ^a   Simoni, Manuela ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Gonadotropin; Gonadotropin receptor; LHCGR; Polymorphism; SNP. FSHR

Indexed keywords

GONADOTROPIN; GONADOTROPIN RECEPTOR;

AMENORRHEA; ARTICLE; BONE METABOLISM; BREAST CANCER; CGB GENE; CONTROLLED OVARIAN STIMULATION; DNA POLYMORPHISM; ENDOMETRIOSIS; EXON; FEMALE FERTILITY; FEMALE INFERTILITY; GENE; GENE STRUCTURE; GENOTYPE; HUMAN; LHB GENE; LHCGR GENE; MALE FERTILITY; MALE INFERTILITY; MENSTRUAL CYCLE; NONHUMAN; OLIGOMENORRHEA; OSTEOPOROSIS; OVARY CANCER; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREDICTION; PREMATURE OVARIAN FAILURE; REPRODUCTION; SPERMATOGENESIS; STIMULATION; TESTIS CANCER;

ANIMALS; FEMALE; FERTILITY; GONADOTROPINS; HUMANS; INFERTILITY; MALE; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; RECEPTORS, GONADOTROPIN; REPRODUCTION;

EID: 84855646730     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-011-9192-2     Document Type: Article

References (205)

1. Simoni M, Gromoll J, Nieschlag E. The follicle-stimulating hormone receptor: Biochemistry, molecular biology, physiology, and pathophysiology. Endocr Rev. 1997;18(6):739-73. (Pubitemid 28009566)
2. Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev. 2002;23(2):141-74.
3. Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: Elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev. 2000;21 (5):551-83.
4. Dias JA, Van Roey P. Structural biology of human follitropin and its receptor. Arch Med Res. 2001;32(6):510-9. (Pubitemid 34031743)
5. Szkudlinski MW, Fremont V, Ronin C, Weintraub BD. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev. 2002;82(2):473-502. (Pubitemid 34654459)
6. Maston G, Ruvolo M. Chorionic gonadotropin has a recent origin within primates and an evolutionary history of selection. Mol Biol Evol. 2002;19(3):320-35. (Pubitemid 34184602)
7. Henke A, Gromoll J. New insights into the evolution of chorionic gonadotrophin. Mol Cell Endocrinol. 2008;291(1- 2):11-9.
8. Nagirnaja L, Rull K, Uusküla L, Hallast P, Grigorova M, Laan M. Genomics and genetics of gonadotropin beta-subunit genes: Unique FSHB and duplicated LHB/CGB loci. Mol Cell Endocrinol. 2010;329(1-2):4-16.
9. Talmadge K, Vamvakopoulos NC, Fiddes JC. Evolution of the genes for the beta subunits of human chorionic gonadotropin and luteinizing hormone. Nature. 1984;5(5946):37-40. (Pubitemid 14132927)
10. Fredriksson R, Lagerström MC, Lundin L, Schiöth HB. The Gprotein- coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63(6):1256-72. (Pubitemid 36627220)
11. Gromoll J, Pekel E, Nieschlag E. The structure and organization of the human follicle-stimulating hormone receptor (FSHR) gene. Genomics. 1996;35(2):308-11. (Pubitemid 26250316)
12. Atger M, Misrahi M, Sar S, Le Flem L, Dessen P, Milgrom E. Structure of the human luteinizing hormone-choriogonadotropin receptor gene: Unusual promoter and 5' non-coding regions. Mol Cell Endocrinol. 1995;111(2):113-23.
13. Nordhoff V, Gromoll J, Simoni M. Constitutively active mutations of G protein-coupled receptors: The case of the human luteinizing hormone and follicle-stimulating hormone receptors. Arch Med Res. 1999;30(6):501-9. (Pubitemid 30067565)
14. Simoni M, Tempfer CB, Destenaves B, Fauser BCJM. Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response. Hum Reprod Update. 2008;14(5):459-84.
15. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science. 2002;296(5576):2225-9. (Pubitemid 34680308)
16. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-5. (Pubitemid 40202029)
17. Barrett JC. Haploview: Visualization and analysis of SNP genotype data. Cold Spring Harb Protoc. 2009 Ott;2009(10):pdb.ip71.
18. Simoni M, Gromoll J, HöppnerW, Kamischke A, Krafft T, Stähle D, et al. Mutational analysis of the follicle-stimulating hormone (FSH) receptor in normal and infertile men: Identification and characterization of two discrete FSH receptor isoforms. J Clin Endocrinol Metab. 1999;84(2):751-5. (Pubitemid 29075716)
19. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab. 2000;85(9):3365-9.
20. Gromoll J, Simoni M. Follicle-stimulating-hormone receptor and twinning. Lancet. 2001;20(9251):230. author reply 231-232.
21. Hodgen GD. The dominant ovarian follicle. Fertil Steril. 1982;38 (3):281-300. (Pubitemid 12013760)
22. Baird DT. A model for follicular selection and ovulation: Lessons from superovulation. J Steroid Biochem. 1987;27(1-3):15-23.
23. Brown JB. Pituitary control of ovarian function-concepts derived from gonadotrophin therapy. Aust N Z J Obstet Gynaecol. 1978;18(1):46-54.
24. Schipper I, Hop WCJ, Fauser BCJM. The Follicle-Stimulating Hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: Duration, rather than magnitude, of FSH increase affects follicle development. J Clin Endocrinol Metab. 1998;83(4):1292-8. (Pubitemid 28496410)
25. Zheng W, Magid M, Kramer E, Chen Y. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol. 1996;148(1):47-53. (Pubitemid 26019642)
26. Greb RR, Grieshaber K, Gromoll J, Sonntag B, Nieschlag E, Kiesel L, et al. A common single nucleotide polymorphism in exon 10 of the human follicle stimulating hormone receptor is a major determinant of length and hormonal dynamics of the menstrual cycle. J Clin Endocrinol Metab. 2005;90(8):4866-72. (Pubitemid 41159384)
27. Gromoll J, Simoni M. Genetic complexity of FSH receptor function. Trends Endocrinol Metab. 2005;16(8):368-73. (Pubitemid 41338742)
28. Nordhoff V, Sonntag B, von Tils D, Götte M, Schüring AN, Gromoll J, et al. Effects of the FSH receptor gene polymorphism p.N680S on cAMP and steroid production in cultured primary human granulosa cells. Reprod Biomed Online [Internet]. 2011 Mag 12 [citato 2011 Lug 29]; Available from: Http://www.ncbi. nlm.nih.gov/pubmed/21680247
29. Loutradis D, Vlismas A, Drakakis P, Antsaklis A. Pharmacogenetics in ovarian stimulation-current concepts. Ann N Y Acad Sci. 2008;1127:10-9.
30. Meyer JM, Eaves LJ, Heath AC, Martin NG. Estimating genetic influences on the age-at-menarche: A survival analysis approach. Am J Med Genet. 1991;39(2):148-54.
31. Kaprio J, Rimpelä A, Winter T, Viken RJ, Rimpelä M, Rose RJ. Common genetic influences on BMI and age at menarche. Hum Biol. 1995;67(5):739-53.
32. Zerbetto I, Gromoll J, Luisi S, Reis FM, Nieschlag E, Simoni M, et al. Follicle-stimulating hormone receptor and DAZL gene polymorphisms do not affect the age of menopause. Fertil Steril. 2008;90(6):2264-8.
33. Achrekar SK, Modi DN, Meherji PK, Patel ZM, Mahale SD. Follicle stimulating hormone receptor gene variants in women with primary and secondary amenorrhea. J Assist Reprod Genet. 2010;27(6):317-26.
34. Sowers MR, Jannausch ML, McConnell DS, Kardia SR, Randolph JF. Menstrual cycle markers of ovarian aging and sex steroid hormone genotypes. Am J Med. 2006;119(9 Suppl 1): S31-43. (Pubitemid 44292100)
35. Grigorova M, Punab M, Ausmees K, Laan M. FSHB promoter polymorphism within evolutionary conserved element is associated with serum FSH level in men. Hum Reprod. 2008;23 (9):2160-6.
36. Fauser BCJM, Diedrich K, Devroey P. Predictors of ovarian response: Progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update. 2008;14 (1):1-14.
37. Sudo S, Kudo M, Wada S, Sato O, Hsueh AJW, Fujimoto S. Genetic and functional analyses of polymorphisms in the human FSH receptor gene. Mol Hum Reprod. 2002;8(10):893-9. (Pubitemid 35174921)
38. de Castro F, Ruiz R, Montoro L, Pérez-Hernández D, Sánchez- Casas Padilla E, Real LM, et al. Role of follicle-stimulating hormone receptor Ser680Asn polymorphism in the efficacy of follicle-stimulating hormone. Fertil Steril. 2003;80(3):571-6. (Pubitemid 37102868)
39. de Castro F, Morón FJ, Montoro L, Galán JJ, Hernández DP, Padilla ES, et al. Human controlled ovarian hyperstimulation outcome is a polygenic trait. Pharmacogenetics. 2004;14 (5):285-93. (Pubitemid 38638915)
40. Jun JK, Yoon JS, Ku S, Choi YM, Hwang KR, Park SY, et al. Follicle-stimulating hormone receptor gene polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVF-ET. J Hum Genet. 2006;51(8):665-70. (Pubitemid 44325666)
41. Loutradis D, Patsoula E, Minas V, Koussidis GA, Antsaklis A, Michalas S, et al. FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs. J Assist Reprod Genet. 2006;23(4):177-84. (Pubitemid 43873809)
42. Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, et al. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online. 2009;18(1):9-14.
43. Behre HM, Greb RR, Mempel A, Sonntag B, Kiesel L, Kaltwasser P, et al. Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: A pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet Genomics. 2005;15(7):451-6. (Pubitemid 41017593)
44. Klinkert ER, te Velde ER, Weima S, van Zandvoort PM, Hanssen RGJM, Nilsson PR, et al. FSH receptor genotype is associated with pregnancy but not with ovarian response in IVF. Reprod Biomed Online. 2006;13(5):687-95. (Pubitemid 44760893)
45. Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD. Poor ovarian response to gonadotrophin stimulation is associated with FSH receptor polymorphism. Reprod Biomed Online. 2009;18(4):509-15.
46. Ochsenkühn R, von Schönfeldt V, Simoni M. FSH receptor polymorphisms and ovarian function. Texte intégral de l'article Printable version FSH receptor polymorphisms and ovarian function. MT/médecine de la reproduction, gynécologie et endocrinologie. 2009;11(4):265-70.
47. Richter-Unruh A, Martens JWM, Verhoef-Post M, Wessels HT, Kors WA, Sinnecker GHG, et al. Leydig cell hypoplasia: Cases with new mutations, new polymorphisms and cases without mutations in the luteinizing hormone receptor gene. Clin Endocrinol (Oxf). 2002;56(1):103-12. (Pubitemid 34107327)
48. Powell BL, Piersma D, Kevenaar ME, van Staveren IL, Themmen APN, Iacopetta BJ, et al. Luteinizing hormone signaling and breast cancer: Polymorphisms and age of onset. J Clin Endocrinol Metab. 2003;88(4):1653-7. (Pubitemid 36623383)
49. Themmen APN. An update of the pathophysiology of human gonadotrophin subunit and receptor gene mutations and polymorphisms. Reproduction. 2005;130(3):263-74. (Pubitemid 41320751)
50. Rull K, Laan M. Expression of beta-subunit of HCG genes during normal and failed pregnancy. Hum Reprod. 2005;20 (12):3360-8. (Pubitemid 41742513)
51. Rull K, Nagirnaja L, Ulander V, Kelgo P, Margus T, Kaare M, et al. Chorionic gonadotropin beta-gene variants are associated with recurrent miscarriage in two European populations. J Clin Endocrinol Metab. 2008;93(12):4697-706.
52. Uusküla L, Rull K, Nagirnaja L, Laan M. Methylation allelic polymorphism (MAP) in chorionic gonadotropin beta5 (CGB5) and its association with pregnancy success. J Clin Endocrinol Metab. 2011;96(1):E199-207.
53. Nastri CO, Ferriani RA, Rocha IA, Martins WP. Ovarian hyperstimulation syndrome: Pathophysiology and prevention. J Assist Reprod Genet. 2010;27(2-3):121-8.
54. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update. 2002;8(6):559-77. (Pubitemid 35452781)
55. Vlahos NF, Gregoriou O. Prevention and management of ovarian hyperstimulation syndrome. Ann N Y Acad Sci. 2006;1092:247-64. (Pubitemid 47092342)
56. Nappi RG, Di Naro E, D'Aries AP, Nappi L. Natural pregnancy in hypothyroid woman complicated by spontaneous ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 1998;178 (3):610-1. (Pubitemid 28207520)
57. Michaelson-Cohen R, Altarescu G, Beller U, Reens R, Halevy- Shalem T, Eldar-Geva T. Does elevated human chorionic gonadotropin alone trigger spontaneous ovarian hyperstimulation syndrome? Fertil Steril. 2008;90(5):1869-74.
58. Dieterich M, Bolz M, Reimer T, Costagliola S, Gerber B. Two different entities of spontaneous ovarian hyperstimulation in a woman with FSH receptor mutation. Reprod Biomed Online. 2010;20(6):751-8.
59. Rodien P, Beau I, Vasseur C. Ovarian hyperstimulation syndrome (OHSS) due to mutations in the follicle-stimulating hormone receptor. Ann Endocrinol (Paris). 2010;71(3):206-9.
60. Kerkelä E, Skottman H, Friden B, Bjuresten K, Kere J, Hovatta O. Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormone receptor genes as the cause of ovarian hyperstimulation syndrome. Fertil Steril. 2007;87 (3):603-6. (Pubitemid 46385967)
61. Daelemans C, Smits G, de Maertelaer V, Costagliola S, Englert Y, Vassart G, et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab. 2004;89(12):6310-5. (Pubitemid 39628451)
62. Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD. Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women. Fertil Steril. 2009;91(2):432-9.
63. Chen S, Chou C, Lin C, Lee H, Wu J, Lu H, et al. Signal mechanisms of vascular endothelial growth factor and interleukin- 8 in ovarian hyperstimulation syndrome: Dopamine targets their common pathways. Hum Reprod. 2010;25(3):757-67.
64. Peitsidis P, Agrawal R. Role of vascular endothelial growth factor in women with PCO and PCOS: A systematic review. Reprod Biomed Online. 2010;20(4):444-52.
65. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370(9588):685-97. (Pubitemid 47285318)
66. Du J, Zhang W, Guo L, Zhang Z, Shi H, Wang J, et al. Two FSHR variants, haplotypes and meta-analysis in Chinese women with premature ovarian failure and polycystic ovary syndrome. Mol Genet Metab. 2010;100(3):292-5.
67. Tong Y, Liao WX, Roy AC, Ng SC. Absence of mutations in the coding regions of follicle-stimulating hormone receptor gene in Singapore Chinese women with premature ovarian failure and polycystic ovary syndrome. Horm Metab Res. 2001;33(4):221-6. (Pubitemid 32452798)
68. Laven JSE, Mulders AGMGJ, Suryandari DA, Gromoll J, Nieschlag E, Fauser BCJM, et al. Follicle-stimulating hormone receptor polymorphisms in women with normogonadotropic anovulatory infertility. Fertil Steril. 2003;80(4):986-92. (Pubitemid 37230037)
69. Orio F, Ferrarini E, Cascella T, Dimida A, Palomba S, Gianetti E, et al. Genetic analysis of the follicle stimulating hormone receptor gene in women with polycystic ovary syndrome. J Endocrinol Invest. 2006;29(11):975-82. (Pubitemid 46344231)
70. Unsal T, Konac E, Yesilkaya E, Yilmaz A, Bideci A, Ilke Onen H, et al. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J Assist Reprod Genet. 2009;26 (4):205-16.
71. Valkenburg O, Uitterlinden AG, Piersma D, Hofman A, Themmen APN, de Jong FH, et al. Genetic polymorphisms of GnRH and gonadotrophic hormone receptors affect the phenotype of polycystic ovary syndrome. Hum Reprod. 2009;24(8):2014-22.
72. Gu B, Park J, Baek K. Genetic variations of follicle stimulating hormone receptor are associated with polycystic ovary syndrome. Int J Mol Med. 2010;26(1):107-12.
73. Overbeek A, Kuijper EAM, Hendriks ML, Blankenstein MA, Ketel IJG, Twisk JWR, et al. Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Serpolymorphism in polycystic ovary syndrome. Hum Reprod. 2009;24(8):2007-13.
74. Tong Y, Liao WX, Roy AC, Ng SC. Association of AccI polymorphism in the follicle-stimulating hormone beta gene with polycystic ovary syndrome. Fertil Steril. 2000;74(6):1233-6.
75. Lamminen T, Jokinen P, Jiang M, Pakarinen P, Simonsen H, Huhtaniemi I. Human FSH beta subunit gene is highly conserved. Mol Hum Reprod. 2005;11(8):601-5. (Pubitemid 41488023)
76. Nilsson C, Jiang M, Pettersson K, Iitiä A, Mäkelä M, Simonsen H, et al. Determination of a common genetic variant of luteinizing hormone using DNA hybridization and immunoassays. Clin Endocrinol (Oxf). 1998;49(3):369-76. (Pubitemid 28448948)
77. Pettersson K, Ding YQ, Huhtaniemi I. An immunologically anomalous luteinizing hormone variant in a healthy woman. J Clin Endocrinol Metab. 1992;74(1):164-71.
78. Suganuma N, Furui K, Kikkawa F, Tomoda Y, Furuhashi M. Effects of the mutations (Trp8?Arg and Ile15?Thr) in human luteinizing hormone (LH) beta-subunit on LH bioactivity in vitro and in vivo. Endocrinology. 1996;137(3):831-8.
79. Jiang M, Pakarinen P, Zhang FP, El-Hefnawy T, Koskimies P, Pettersson K, et al. A common polymorphic allele of the human luteinizing hormone beta-subunit gene: Additional mutations and differential function of the promoter sequence. Hum Mol Genet. 1999;8(11):2037-46. (Pubitemid 29458731)
80. Cramer DW, Petterson KS, Barbieri RL, Huhtaniemi IT. Reproductive hormones, cancers, and conditions in relation to a common genetic variant of luteinizing hormone. Hum Reprod. 2000;15(10):2103-7.
81. Tapanainen JS, Koivunen R, Fauser BCJM, Taylor AE, Clayton RN, Rajkowa M, et al. A new contributing factor to polycystic ovary syndrome: The genetic variant of luteinizing hormone. J Clin Endocrinol Metab. 1999;84(5):1711-5. (Pubitemid 30644281)
82. Kevenaar ME, Laven JSE, Fong SL, Uitterlinden AG, de Jong FH, Themmen APN, et al. A functional anti-mullerian hormone gene polymorphism is associated with follicle number and androgen levels in polycystic ovary syndrome patients. J Clin Endocrinol Metab. 2008;93(4):1310-6. (Pubitemid 351519726)
83. van Houten ELAF, Themmen APN, Visser JA. Anti-Müllerian hormone (AMH): Regulator and marker of ovarian function. Ann Endocrinol (Paris). 2010;71(3):191-7.
84. Xita N, Lazaros L, Georgiou I, Tsatsoulis A. CYP19 gene: A genetic modifier of polycystic ovary syndrome phenotype. Fertil Steril. 2010;94(1):250-4.
85. Laisk T, Haller-Kikkatalo K, Laanpere M, Jakovlev U, Peters M, Karro H, et al. Androgen receptor epigenetic variations influence early follicular phase gonadotropin levels. Acta Obstet Gynecol Scand. 2010;89(12):1557-63.
86. Ke L, Che Y, Cao Y,Wu X, Hu Y, Sun H, et al. Polymorphisms of the HSD17B6 and HSD17B5 genes in Chinese women with polycystic ovary syndrome. J Womens Health (Larchmt). 2010;19(12):2227-32.
87. Mu Y, Liu J, Wang B, Wen Q, Wang J, Yan J, et al. Interleukin 1 beta (IL-1ß) promoter C [-511] T polymorphism but not C [+3953] T polymorphism is associated with polycystic ovary syndrome. Endocrine. 2010;37(1):71-5.
88. Yang Y, Qiao J, Li M. Association of polymorphisms of interleukin-18 gene promoter region with polycystic ovary syndrome in Chinese population. Reprod Biol Endocrinol. 2010;8:125.
89. Vural P, Küskü-Kiraz Z, Dodru-Abbasodlu S, Cil E, Karadad B, Akgül C, et al. Vascular endothelial growth factor -2578 A/C, -460 T/C and +405 G/C polymorphisms in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):57-60.
90. Sproul K, Jones MR, Mathur R, Azziz R, Goodarzi MO. Association study of four key folliculogenesis genes in polycystic ovary syndrome. BJOG. 2010;117(6):756-60.
91. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67(4):604-6. (Pubitemid 16116286)
92. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril. 1990;53(5):804-10. (Pubitemid 20180467)
93. Conway GS. Premature ovarian failure. Br Med Bull. 2000;56 (3):643-9. (Pubitemid 32041658)
94. Welt CK. Primary ovarian insufficiency: A more accurate term for premature ovarian failure. Clin Endocrinol (Oxf). 2008;68 (4):499-509. (Pubitemid 351388699)
95. DeVosM,Devroey P, Fauser BCJM. Primary ovarian insufficiency. Lancet. 2010;376(9744):911-21.
96. Woad KJ, Watkins WJ, Prendergast D, Shelling AN. The genetic basis of premature ovarian failure. Aust N Z J Obstet Gynaecol. 2006;46(3):242-4. (Pubitemid 44056734)
97. Persani L, Rossetti R, Cacciatore C, Bonomi M. Primary ovarian insufficiency: X chromosome defects and autoimmunity. J Autoimmun. 2009;33(1):35-41.
98. van Dooren MF, Bertoli-Avellab AM, Oldenburg RA. Premature ovarian failure and gene polymorphisms. Curr Opin Obstet Gynecol. 2009;21(4):313-7.
99. Christin-Maitre S, Tachdjian G. Genome-wide association study and premature ovarian failure. Ann Endocrinol (Paris). 2010;71 (3):218-21.
100. Aittomäki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell. 1995;82(6):959-68.
101. Ghadami M, El-Demerdash E, Salama SA, Binhazim AA, Archibong AE, Chen X, et al. Toward gene therapy of premature ovarian failure: Intraovarian injection of adenovirus expressing human FSH receptor restores folliculogenesis in FSHR(-/-) FORKO mice. Mol Hum Reprod. 2010;16(4):241-50.
102. Shelling AN, Burton KA, Chand AL, van Ee CC, France JT, Farquhar CM, et al. Inhibin: A candidate gene for premature ovarian failure. Hum Reprod. 2000;15(12):2644-9. (Pubitemid 32000524)
103. Rannikko A, Pakarinen P, Manna PR, Beau I, Misrahi M, Aittomäki K, et al. Functional characterization of the human FSH receptor with an inactivating Ala189Val mutation. Mol Hum Reprod. 2002;8(4):311-7. (Pubitemid 34303238)
104. Conway GS, Conway E, Walker C, Hoppner W, Gromoll J, Simoni M. Mutation screening and isoform prevalence of the follicle stimulating hormone receptor gene in women with premature ovarian failure, resistant ovary syndrome and polycystic ovary syndrome. Clin Endocrinol (Oxf). 1999;51(1):97-9. (Pubitemid 29339541)
105. Vilodre LC, Kohek MBF, Spritzer PM. Screening of folliclestimulating hormone receptor gene in women with premature ovarian failure in southern Brazil and associations with phenotype. J Endocrinol Invest. 2008;31(6):552-7.
106. Doherty E, Pakarinen P, Tiitinen A, Kiilavuori A, Huhtaniemi I, Forrest S, et al. A Novel mutation in the FSH receptor inhibiting signal transduction and causing primary ovarian failure. J Clin Endocrinol Metab. 2002;87(3):1151-5. (Pubitemid 36121080)
107. Bulun SE. Endometriosis. N Engl J Med. 2009;360(3):268-79.
108. Falconer H, D'Hooghe T, Fried G. Endometriosis and genetic polymorphisms. Obstet Gynecol Surv. 2007;62(9):616-28. (Pubitemid 47267734)
109. Tempfer CB, Simoni M, Destenaves B, Fauser BCJM. Functional genetic polymorphisms and female reproductive disorders: Part II-endometriosis. Hum Reprod Update. 2009;15(1):97-118.
110. Liao WX, Roy AC, Chan C, Arulkumaran S, Ratnam SS. A new molecular variant of luteinizing hormone associated with female infertility. Fertil Steril. 1998;69(1):102-6. (Pubitemid 28073001)
111. Mafra FA, Bianco B, Christofolini DM, Souza AMB, Zulli K, Barbosa CP. Luteinizing hormone beta-subunit gene (LHbeta) polymorphism in infertility and endometriosis-associated infertility. Eur J Obstet Gynecol Reprod Biol. 2010;151(1):66-9.
112. Wang H, Cheng B, Wu H, Yen C, Liu C, Chao A, et al. A mutant single nucleotide polymorphism of follicle-stimulating hormone receptor is associated with a lower risk of endometriosis. Fertil Steril [Internet]. 2010 Set 2 [citato 2010 Dic 9];Available from: Http://www.ncbi.nlm.nih.gov/pubmed/20817169
113. Layman LC, McDonough PG. Mutations of follicle stimulating hormone-beta and its receptor in human and mouse: Genotype/ phenotype. Mol Cell Endocrinol. 2000;161(1-2):9-17. (Pubitemid 30201644)
114. Wunsch A, Ahda Y, Banaz-Yasar F, Sonntag B, Nieschlag E, Simoni M, et al. Single-nucleotide polymorphisms in the promoter region influence the expression of the human follicle-stimulating hormone receptor. Fertil Steril. 2005;84 (2):446-53. (Pubitemid 41125268)
115. Asatiani K, Gromoll J, Eckardstein SV, Zitzmann M, Nieschlag E, Simoni M. Distribution and function of FSH receptor genetic variants in normal men. Andrologia. 2002;34(3):172-6. (Pubitemid 34639200)
116. Ahda Y, Gromoll J, Wunsch A, Asatiani K, Zitzmann M, Nieschlag E, et al. Follicle-stimulating hormone receptor gene haplotype distribution in normozoospermic and azoospermic men. J Androl. 2005;26(4):494-9. (Pubitemid 40847861)
117. Lend AK, Belousova A, Haller-Kikkatalo K, Punab M, Poolamets O, Peters M, et al. Follicle-stimulating hormone receptor gene haplotypes and male infertility in estonian population and metaanalysis. Syst Biol Reprod Med. 2010;56(1):84-90.
118. Balkan M, Gedik A, Akkoc H, Izci Ay O, Erdal ME, Isi H, et al. FSHR single nucleotide polymorphism frequencies in proven fathers and infertile men in Southeast Turkey. J Biomed Biotechnol. 2010;2010:640318.
119. Nakayama T, Kuroi N, Sano M, Tabara Y, Katsuya T, Ogihara T, et al. Mutation of the follicle-stimulating hormone receptor gene 5'-untranslated region associated with female hypertension. Hypertension. 2006;48(3):512-8. (Pubitemid 44253748)
120. Plant TM, Marshall GR. The functional significance of FSH in spermatogenesis and the control of its secretion in male primates. Endocr Rev. 2001;22(6):764-86. (Pubitemid 34214294)
121. Grigorova M, Rull K, Laan M. Haplotype structure of FSHB, the beta-subunit gene for fertility-associated follicle-stimulating hormone: Possible influence of balancing selection. Ann Hum Genet. 2007;71(Pt 1):18-28. (Pubitemid 44857679)
122. Matthews CH, Borgato S, Beck-Peccoz P, Adams M, Tone Y, Gambino G, et al. Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nat Genet. 1993;5(1):83-6. (Pubitemid 23261525)
123. Layman L, Lee E, Peak D, Namnoum A, Vu K, Van Lingen B, et al. Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone ß-subunit gene. N Engl J Med. 1997;337(9):607-11. (Pubitemid 27360761)
124. Lindstedt G, Nyström E, Matthews C, Ernest I, Janson PO, Chatterjee K. Follitropin (FSH) deficiency in an infertile male due to FSHß gene mutation. A syndrome of normal puberty and virilization but under-developed testicles with azoospermia, low FSH but high lutropin and normal serum testosterone concentrations. Clin Chem Lab Med. 1998;36(8):663-5. (Pubitemid 28468327)
125. Phillip M, Arbelle JE, Segev Y, Parvari R. Male hypogonadism due to a mutation in the gene for the beta-subunit of folliclestimulating hormone. N Engl J Med. 1998;338(24):1729-32.
126. Clark AD, Layman LC. Analysis of the Cys82Arg mutation in follicle-stimulating hormone beta (FSHbeta) using a novel FSH expression vector. Fertil Steril. 2003;79(2):379-85. (Pubitemid 36144064)
127. Huhtaniemi I. Mutations affecting gonadotropin secretion and action. Horm Res. 2003;60 Suppl 3:21-30. (Pubitemid 37548199)
128. Giltay JC, Deege M, Blankenstein RA, Kastrop PMM, Wijmenga C, Lock TTWT. Apparent primary follicle-stimulating hormone deficiency is a rare cause of treatablemale infertility. Fertil Steril. 2004;81(3):693-6. (Pubitemid 38376132)
129. Berger K, Souza H, Brito VN, d'Alva CB, Mendonca BB, Latronico AC. Clinical and hormonal features of selective follicle-stimulating hormone (FSH) deficiency due to FSH beta-subunit gene mutations in both sexes. Fertil Steril. 2005;83(2):466-70. (Pubitemid 40221809)
130. Lofrano-Porto A, Casulari LA, Nascimento PP, Giacomini L, Naves LA, da Motta LDC, et al. Effects of follicle-stimulating hormone and human chorionic gonadotropin on gonadal steroidogenesis in two siblings with a follicle-stimulating hormone beta subunit mutation. Fertil Steril. 2008;90(4):1169-74.
131. Ciccone NA, Xu S, Lacza CT, Carroll RS, Kaiser UB. Frequency-dependent regulation of follicle-stimulating hormone beta by pulsatile gonadotropin-releasing hormone is mediated by functional antagonism of bZIP transcription factors. Mol Cell Biol. 2010;30(4):1028-40.
132. Kottler M, Chou Y, Chabre O, Richard N, Polge C, Brailly- Tabard S, et al. A new FSHbeta mutation in a 29-year-old woman with primary amenorrhea and isolated FSH deficiency: Functional characterization and ovarian response to human recombinant FSH. Eur J Endocrinol. 2010;162(3):633-41.
133. Grigorova M, Punab M, Poolamets O, Kelgo P, Ausmees K, Korrovits P, et al. Increased prevalance of the -211 T allele of follicle stimulating hormone (FSH) beta subunit promoter polymorphism and lower serum FSH in infertile men. J Clin Endocrinol Metab. 2010;95(1):100-8.
134. Miller WL, Shafiee-Kermani F, Strahl BD, Huang H. The nature of FSH induction by GnRH. Trends Endocrinol Metab. 2002;13 (6):257-63. (Pubitemid 36733971)
135. Hoogendoorn B, Coleman SL, Guy CA, Smith K, Bowen T, Buckland PR, et al. Functional analysis of human promoter polymorphisms. Hum Mol Genet. 2003;12(18):2249-54. (Pubitemid 37160869)
136. Knobil E, Neill JD. Knobil and Neill's physiology of reproduction. Gulf Professional Publishing; 2006.
137. Toppari J, Kaleva M, Virtanen HE, Main KM, Skakkebaek NE. Luteinizing hormone in testicular descent. Mol Cell Endocrinol. 2007;269(1-2):34-7. (Pubitemid 46505182)
138. Simoni M, Tüttelmann F, Michel C, Böckenfeld Y, Nieschlag E, Gromoll J. Polymorphisms of the luteinizing hormone/chorionic gonadotropin receptor gene: Association with maldescended testes and male infertility. Pharmacogenet Genomics. 2008;18 (3):193-200. (Pubitemid 351323233)
139. Catena R, Argentini M, Martianov I, Parello C, Brancorsini S, Parvinen M, et al. Proteolytic cleavage of ALF into alpha- and beta-subunits that form homologous and heterologous complexes with somatic TFIIA and TRF2 in male germ cells. FEBS Lett. 2005;579(16):3401-10. (Pubitemid 40800289)
140. Huang M, Wang H, Li J, Zhou Z, Du Y, Lin M, et al. Involvement of ALF in human spermatogenesis and male infertility. Int J Mol Med. 2006;17(4):599-604.
141. Lamminen T, Huhtaniemi I. A common genetic variant of luteinizing hormone; relation to normal and aberrant pituitarygonadal function. Eur J Pharmacol. 2001;414(1):1-7. (Pubitemid 32174869)
142. Kaleva M, Virtanen H, Haavisto A, Main K, Skakkebaek NE, Huhtaniemi I, et al. Does variant luteinizing hormone (V-LH) predispose to improper testicular position in late pregnancy? Pediatr Res. 2005;58(3):447-50. (Pubitemid 41254505)
143. Martin AC. Osteoporosis in men: A review of endogenous sex hormones and testosterone replacement therapy. J Pharm Pract. 2011;24(3):307-15.
144. Zaidi M, Alam AS, Shankar VS, Bax BE, Bax CM, Moonga BS, et al. Cellular biology of bone resorption. Biol Rev Camb Philos Soc. 1993;68(2):197-264. (Pubitemid 23160585)
145. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332(5):305-11.
146. Lindsay R. Hormones and bone health in postmenopausal women. Endocrine. 2004;24(3):223-30. (Pubitemid 41271153)
147. Roggia C, Gao Y, Cenci S, Weitzmann M, Toraldo G, Isaia G, et al. Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA. 2001;98(24):13960-5.
148. Cenci S, Toraldo G, Weitzmann M, Roggia C, Gao Y, Qian W, et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-?-induced class II transactivator. Proc Natl Acad Sci USA. 2003;100(18):10405-10. (Pubitemid 37071891)
149. Shevde N, Bendixen A, Dienger K, Pike J. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA. 2000;97(14):7829-34. (Pubitemid 30460733)
150. Srivastava S, Toraldo G, Weitzmann M, Cenci S, Ross F, Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-?B ligand (RANKL)-induced JNK activation. J Biol Chem. 2001;276(12):8836-40.
151. McCauley L, Tözüm T, Rosol T. Estrogen receptors in skeletal metabolism: Lessons from genetically modified models of receptor function. Crit Rev Eukaryot Gene Expr. 2002;12 (2):89-100. (Pubitemid 37158228)
152. Windahl S, Andersson G, Gustafsson J. Elucidation of estrogen receptor function in bone with the use of mouse models. Trends Endocrinol Metab. 2002;13(5):195-200. (Pubitemid 36733979)
153. Lindberg M, Alatalo S, Halleen J, Mohan S, Gustafsson J, Ohlsson C. Estrogen receptor specificity in the regulation of the skeleton in female mice. J Endocrinol. 2001;171(2):229-36. (Pubitemid 33061699)
154. Yeh J, Chen M, Aloia J. Ovariectomy-induced high turnover in cortical bone is dependent on pituitary hormone in rats. Bone. 1996;18(5):443-50. (Pubitemid 26152307)
155. Yeh J, Chen M, Aloia J. Effects of 17ß-estradiol administration on cortical and cancellous bone of ovariectomized rats with and without hypophysectomy. Bone. 1997;20(5):413-20. (Pubitemid 27230445)
156. Sowers M, Greendale G, Bondarenko I, Finkelstein J, Cauley J, Neer R, et al. Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int. 2003;14(3):191-7. (Pubitemid 40826231)
157. Devleta B, Adem B, Senada S. Hypergonadotropic amenorrhea and bone density: New approach to an old problem. J Bone Miner Metab. 2004;22(4):360-4. (Pubitemid 38980953)
158. Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M. Folliclestimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci USA. 2006;103(40):14925-30. (Pubitemid 44527830)
159. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, et al. FSH directly regulates bone mass. Cell. 2006;125(2):247-60.
160. Baron R. FSH versus estrogen: Who's guilty of breaking bones? Cell Metab. 2006;3(5):302-5.
161. Gao J, Tiwari-Pandey R, Samadfam R, Yang Y, Miao D, Karaplis AC, et al. Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone. Endocrinology. 2007;148(6):2613-21. (Pubitemid 46984812)
162. Allan CM, Kalak R, Dunstan CR, McTavish KJ, Zhou H, Handelsman DJ, et al. Follicle-stimulating hormone increases bone mass in female mice. Proc Natl Acad Sci USA. 2010;107 (52):22629-34.
163. Rendina D, Gianfrancesco F, De Filippo G, Merlotti D, Esposito T, Mingione A, et al. FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur J Endocrinol. 2010;163(1):165-72.
164. Seibel MJ, Dunstan CR, Zhou H, Allan CM, Handelsman DJ. Sex steroids, not FSH, influence bone mass. Cell. 2006;127 (6):1079. author reply 1080-1081. (Pubitemid 44894538)
165. Castelo-Branco C, León M, Durán M, Balasch J. Folliclestimulating hormone does not directly regulate bone mass in human beings: Evidence from nature. Fertil Steril. 2008;90 (6):2211-6.
166. Rouach V, Katzburg S, Koch Y, Stern N, Somjen D. Bone loss in ovariectomized rats: Dominant role for estrogen but apparently not for FSH. J Cell Biochem. 2011;112(1):128-37.
167. Krum SA. Direct transcriptional targets of sex steroid hormones in bone. J Cell Biochem. 2011;112(2):401-8.
168. Rauhio A, Uusi-Rasi K, Kunnas T, Nikkari ST, Kannus P, Sievänen H. Estrogen receptor-1 genotype is associated with bone structure in premenopausal obese women. Maturitas [Internet]. 2011 Gen 7 [citato 2011 Gen 28]; Available from: Http://www.ncbi.nlm.nih.gov/pubmed/21216543
169. Zhang X, Dai J, Long Y, Wu H, Li X, Ding Y. Correlation of estrogen receptor alpha gene polymorphisms and bone mineral density in Chinese women with chronic periodontitis. Chin Med J. 2010;123(22):3262-7.
170. Erdogan MO, Yýldýz H, Artan S, Solak M, Tascýodlu F, Dündar U, et al. Association of estrogen receptor alpha and collagen type I alpha 1 gene polymorphisms with bone mineral density in postmenopausal women. Osteoporos Int [Internet]. 2010 Giu 8 [citato 2011 Gen 28]; Available from: Http://www.ncbi.nlm.nih. gov/pubmed/20532479
171. Harsløf T, Husted LB, Carstens M, Stenkjaer L, Langdahl BL. Genotypes and haplotypes of the estrogen receptor genes, but not the retinoblastoma-interacting zinc finger protein 1 gene, are associated with osteoporosis. Calcif Tissue Int. 2010;87(1):25-35.
172. Kim SY, Kim HH, Nam CM, Kim HC, Suh I, Kang BY. Association of estrogen receptor-alpha gene polymorphism with pathogenesis of osteoporosis in Korean vegetarian men. Med Princ Pract. 2010;19(3):200-5.
173. Ichikawa S, Koller DL, Padgett LR, Lai D, Hui SL, Peacock M, et al. Replication of previous genome-wide association studies of bone mineral density in premenopausal American women. J Bone Miner Res. 2010;25(8):1821-9.
174. Jeedigunta Y, Bhoomi Reddy PR, Kolla VK, Munshi A, Ananthapur V, Narasimulu G, et al. Association of estrogen receptor alpha gene polymorphisms with BMD and their affect on estradiol levels in pre- and postmenopausal women in south Indian population from Andhra Pradesh. Clin Chim Acta. 2010;411(7-8):597-600.
175. Elfassihi L, Giroux S, Bureau A, Laflamme N, Cole DE, Rousseau F. Association with replication between estrogenrelated receptor gamma (ESRRgamma) polymorphisms and bone phenotypes in women of European ancestry. J Bone Miner Res. 2010;25(4):901-11.
176. Drake MT, McCready LK, Hoey KA, Atkinson EJ, Khosla S. Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab. 2010;95(11):5063-8.
177. D'Andrilli G, Giordano A, Bovicelli A. Epithelial ovarian cancer: The role of cell cycle genes in the different histotypes. Open Clin Cancer J. 2008;2:7-12.
178. Yamano T, Morii E, Arai I, Takada T, Kubota K, Sato M, et al. Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis. Int J Clin Oncol. 2010;15 (6):621-5.
179. Zagouri F, Dimopoulos MA, Bournakis E, Papadimitriou CA. Molecular markers in epithelial ovarian cancer: Their role in prognosis and therapy. Eur J Gynaecol Oncol. 2010;31(3):268-77.
180. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998;90(23):1774-86. (Pubitemid 28559889)
181. Ji Q, Liu PI, Chen PK, Aoyama C. Follicle stimulating hormoneinduced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer. 2004;112(5):803-14. (Pubitemid 39435265)
182. Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol. 1987;139(9):2977-83. (Pubitemid 17157467)
183. Horn D, Fitzpatrick WC, Gompper PT, Ochs V, Bolton-Hansen M, Zarling J, et al. Regulation of cell growth by recombinant oncostatin M. Growth Factors. 1990;2(2-3):157-65. (Pubitemid 20057753)
184. Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, et al. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem. 1996;271(51):32635-43. (Pubitemid 27008685)
185. Douglas AM, Goss GA, Sutherland RL, Hilton DJ, Berndt MC, Nicola NA, et al. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene. 1997;14(6):661-9. (Pubitemid 27095857)
186. Yang CQ, Chan KYK, Ngan HYS, Khoo US, Chiu PM, Chan QKY, et al. Single nucleotide polymorphisms of folliclestimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis. 2006;27(7):1502-6. (Pubitemid 43985424)
187. Heubner M, Riemann K, Otterbach F, Kimmig R, Kasimir-Bauer S, Siffert W, et al. The haplotype of two FSHR polymorphisms in ovarian cancer-a potential role of ethnology in risk modification. Gynecol Oncol. 2009;112(3):486-9.
188. Ludwig AH, Murawska M, Panek G, Timorek A, Kupryjanczyk J. Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome. Endocr Relat Cancer. 2009;16 (3):1005-16.
189. The International HapMap Project. Nature. 2003;426(6968):789-96.
190. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer (1). N Engl J Med. 1992;327(5):319-28.
191. Martin A, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000;92(14):1126-35.
192. Kuijper TM, Ruigrok-Ritstier K, Verhoef-Post M, Piersma D, Bruysters MWP, Berns EMJJ, et al. LH receptor gene expression is essentially absent in breast tumor tissue: Implications for treatment. Mol Cell Endocrinol. 2009;302(1):58-64.
193. Nilsson C, Pettersson K, Millar RP, Coerver KA, Matzuk MM, Huhtaniemi IT. Worldwide frequency of a common genetic variant of luteinizing hormone: An international collaborative research. Fertil Steril. 1997;67(6):998-1004. (Pubitemid 27241889)
194. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2(3):133-40. (Pubitemid 33585924)
195. Piersma D, Berns E, Verhoef-Post M, Uitterlinden A, Braakman I, Pols H, et al. A common polymorphism renders the luteinizing hormone receptor protein more active by improving signal peptide function and predicts adverse outcome in breast cancer patients. J Clin Endocrinol Metab. 2006;91(4):1470-6.
196. Müller T, Gromoll J, Simoni M. Absence of exon 10 of the human luteinizing hormone (LH) receptor impairs LH, but not human chorionic gonadotropin action. J Clin Endocrinol Metab. 2003;88(5):2242-9. (Pubitemid 36549903)
197. Piersma D, Verhoef-Post M, Berns E, Themmen A. LH receptor gene mutations and polymorphisms: An overview. Mol Cell Endocrinol. 2007;260-262:282-6. (Pubitemid 44792342)
198. Saito Y, Tetsuka M, Yue L, Kawamura Y, Maruyama K. Functional role of N-linked glycosylation on the rat melanin-concentrating hormone receptor 1. FEBS Lett. 2003;533(1-3):29-34. (Pubitemid 36206377)
199. Piersma D, Verhoef-Post M, Look MP, Uitterlinden AG, Pols HAP, Berns EMJJ, et al. Polymorphic variations in exon 10 of the luteinizing hormone receptor: Functional consequences and associations with breast cancer.Mol Cell Endocrinol. 2007;276(1-2):63-70.
200. Rapley EA, Nathanson KL. Predisposition alleles for testicular germ cell tumour. Curr Opin Genet Dev. 2010;20(3):225-30.
201. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet. 2006;367(9512):754-65. (Pubitemid 43326294)
202. Ferlin A, Pengo M, Selice R, Salmaso L, Garolla A, Foresta C. Analysis of single nucleotide polymorphisms of FSH receptor gene suggests association with testicular cancer susceptibility. Endocr Relat Cancer. 2008;15(2):429-37. (Pubitemid 351880832)
203. Oosterhuis JW, Looijenga LHJ. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer. 2005;5(3):210-22. (Pubitemid 40314952)
204. Rajpert-De Meyts E. Developmental model for the pathogenesis of testicular carcinoma in situ: Genetic and environmental aspects. Hum Reprod Update. 2006;12(3):303-23.
205. Garolla A, Ferlin A, Vinanzi C, Roverato A, Sotti G, Artibani W, et al. Molecular analysis of the androgen receptor gene in testicular cancer. Endocr Relat Cancer. 2005;12(3):645-55. (Pubitemid 41482998)